Fig. 6.1 Definition of overdiagnosis (From Etzoioni [55]. Used with permission) Fig. 6.2 Association of different treatment strategies with life expectancy and risk of PCa progression. The downhill slope between…
Company/test name Molecular type Primary endpoints Prolaris – cell cycle progression Gene expression (RNA quantification) Risk of biochemical recurrence, metastasis, and disease-specific mortality Genome DX – Decipher biopsy Gene expression (RNA quantification)…
Risk assessment methods: frequency, timing, and triggers Study PSA test (every) DRE (every) Confirmatory biopsy (months) Repeated biopsiesa (every) Optional MRI Triggers for biopsy and/or MRI University of Toronto…
Fig. 14.1 Low-risk prostate cancer DM Patients’ Backgrounds As previous studies demonstrated [14, 15], patients have personal characteristics that may impact on the treatment DM process. Demographic, psychosocial and clinical…
Fig. 11.1 Man on active surveillance for prostate cancer (Gleason 3 + 3) diagnosed in 2010 4 cores of a TRUS standard 12-core biopsy (4 mm maximum cancer core length). The mpMRI…
Treatment 5-year costs, US model (Keegan et al.) 5-year costs, Canada model (Dragomir et al.) Est. lifetime costs, Canada model (Sanyal et al.) Active surveillance $16,699 $2,991 $18,452 Radical prostatectomy…
Name N Intervention Outcome Nordic lifestyle 2011 24 Vigorous exercise > = 3 ×/week, rye PCa progression Diet in PCa 2011 464 Dietary education and telephone counseling × 2 years Clinical progression, TTP…
Fig. 19.1 New risk definitions in prostate cancer. Traffic light system Yellow disease represents a tumour focus greater than 0.2 cc but less than 0.5 cc as predicted by the maximum cancer…
Enrollment criteria PSAD <0.15, clinical stage T1c, Gleason score ≤6, ≤2 positive cores, and ≤50% involvement of any core (preferred); or PSA <10, clinical stage ≤T2a, and Gleason score ≤6 Monitoring PSA + DRE every…
© Springer International Publishing AG 2018Laurence Klotz (ed.)Active Surveillance for Localized Prostate CancerCurrent Clinical Urologyhttps://doi.org/10.1007/978-3-319-62710-6_17 17. Is There a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of…
